What the WHI Actually Tested

The Women's Health Initiative (WHI) was a large set of randomized clinical trials launched in the 1990s to test whether menopausal hormone therapy could prevent chronic disease in postmenopausal women. The two main hormone arms used specific formulations that were widely prescribed at the time.

Women with an intact uterus received conjugated equine estrogens (CEE, 0.625 mg daily) combined with medroxyprogesterone acetate (MPA, 2.5 mg daily), a synthetic progestin. Women who had undergone hysterectomy received CEE alone at the same dose. These were not bioidentical estradiol or natural progesterone; CEE is a mixture of estrogens derived from pregnant mare urine, and MPA is a synthetic progestin chosen for its ability to protect the uterine lining.

Why the Trials Were Stopped Early

The combined CEE + MPA trial was halted in July 2002 after a median of about 5.2–5.6 years. The data and safety monitoring board determined that the test statistic for invasive breast cancer had crossed a pre-specified stopping boundary and that a global index of risks (including coronary heart disease, stroke, and pulmonary embolism) exceeded benefits. Absolute excesses were modest: roughly 7–8 additional coronary events, 8 strokes, 8 pulmonary emboli, and 8 invasive breast cancers per 10,000 women per year, offset by reductions in hip fractures and colorectal cancer.

The CEE-alone trial continued longer but was stopped in 2004 after a median of approximately 7 years because of an increased risk of stroke and no overall benefit for coronary heart disease prevention. Later long-term follow-up has shown that all-cause mortality was not increased with either regimen over nearly two decades.

Relative Risk Versus Absolute Risk in Public Messaging

The original reports and subsequent media coverage emphasized relative risks—for example, a 26% increase in invasive breast cancer or a 29% increase in coronary heart disease with CEE + MPA. Relative risk describes the proportional change and can sound dramatic. Absolute risk, however, places the same numbers in everyday context: those percentages translated into about 8 extra breast cancers and 7 extra coronary events per 10,000 women per year.

When relative figures dominate headlines, the perceived magnitude of harm rises. Absolute figures show that the excess events, while real, were uncommon for any individual woman. This distinction between relative and absolute statistics became one of the most discussed aspects of how WHI findings were communicated to the public and to clinicians.

Clinical and Cultural Aftermath

The rapid dissemination of the results produced a sharp and sustained decline in hormone therapy prescriptions. Primary care physicians, obstetrician-gynecologists, and endocrinologists became markedly more cautious. Many reported feeling concerned about liability or simply uncertain about which patients, if any, remained appropriate candidates. Surveys after the WHI showed that the large majority of providers reduced or stopped initiating oral estrogen and combined estrogen-progestin regimens, and counseling shifted heavily toward risks.

In practical terms, the study led to a broad demonization of female hormone therapy in the public mind and in routine medical practice. Women who had been using hormones for symptom relief or bone protection often discontinued them abruptly. For more than a decade afterward, many clinicians remained reluctant to prescribe systemic hormones even for bothersome menopausal symptoms, and training in nuanced hormone management declined in some specialties.

Putting the Findings in Perspective for Women Today

The WHI tested specific oral formulations in a population whose average age was in the early 60s—older than the typical woman seeking help for menopausal symptoms. Subsequent analyses have highlighted that timing, dose, route, and the particular hormones used all influence the balance of effects. Understanding the original design, the absolute magnitude of the reported risks, and the way those risks were framed helps women and clinicians evaluate current options more carefully.

Hormone decisions remain individual. They depend on age, time since menopause, personal and family history, symptom burden, and the specific preparation under consideration. Clear laboratory evaluation and ongoing monitoring remain essential when any hormone regimen is used.

Coordinated Hormone Evaluation

Women seeking careful assessment of hormone status—whether related to menopause, thyroid function, or broader metabolic markers—benefit from clinicians who review the full context rather than relying on a single historical study. Services available through Vita Bella provide access to supervised hormone and peptide programs that include laboratory monitoring and individualized decision-making.

When additional peptide support is being considered alongside hormone optimization, the same clinical teams at Vita Bella can integrate testing and follow-up to support informed choices.

References

1. Rossouw JE, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288(3):321-333. doi:10.1001/jama.288.3.321

2. Anderson GL, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA. 2004;291(14):1701-1712. doi:10.1001/jama.291.14.1701

3. Manson JE, et al. Menopausal hormone therapy and long-term all-cause and cause-specific mortality: the Women's Health Initiative randomized trials. JAMA. 2017;318(10):927-938. doi:10.1001/jama.2017.11217

4. Manson JE, et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. JAMA. 2013;310(13):1353-1368. doi:10.1001/jama.2013.278040

5. Hersh AL, Stefanick ML, Stafford RS. National use of postmenopausal hormone therapy: annual trends and response to recent evidence. JAMA. 2004;291(1):47-53. doi:10.1001/jama.291.1.47

6. Sangi-Haghpeykar H, Poindexter AN 3rd. Self-reported changes in providers' hormone therapy prescribing and counseling practices after the Women's Health Initiative. Menopause. 2010;17(6):1125-1131.